Here’s Why Immune Design is Down 6.8% Since the Last Earnings Report
Plummeting 6.8%, way outperforming the market, Immune Design Corp. (NASDAQ:$IMDZ)’s shares are suffering a serious outlook.
Let’s take a look back on Immune Design’s last earnings report.
Narrower-than-expected Loss in Q2
…
This Part of Bioverativ’s Pipeline Could Be a Key Driver For Long-Term Growth
Just last month, Bioverativ (NASDAQ:$BIVV) and Invicro signed a strategic collaboration in developing advanced imaging technologies for the diagnosis and treatment of joint diseases for patients with hemophilia.
In June 2017, Bioverativ acquired …
Gilead Sciences Stock Finally Sees New Uptrend Amid Multi-Year Lows
After a long slump of near multi-year lows, biotech giant Gilead Sciences Inc. (NASDAQ:$GILD), finally saw a recent breakout. This has led to significant buying interest that has lifted the stock into an uptrend that …
Why Sarepta Therapeutics Stock Rose 11% Today
During Wednesday Morning trading, Sarepta Therapeutics (NASDAQ:$SRPT) rose almost 11% on elevated volume. The stock’s outstanding performance undeniably was encouraged by news of optimal results from an early-stage muscle biopsy study for its experimental Duchenne …
Lung Disease Drug Sends Insmed’s Stock Soaring
As of pre-market trading Tuesday, shares of Insmed Inc. (NASDAQ:$ INSM) more than doubled. This came after the company announced that its new drug, an inhaled antibiotic known as Alis, successfully treated patients with a …
ImmunoGen had an Impressive 12% Climb Today
The latest teaser in the biotechnology sector: Irish biotech company Jazz Pharmaceuticals (NASDAQ:$JAZZ) has signed a deal with ImmunoGen Inc. (NASDAQ:$IMGN) in the development of drugs in the Massachusetts-based company pipelines. This sent shares soaring …
The Market Empties On Otonomy Inc. Stock
Following truly abysmal results from a pivotal Phase 3 trial for its steroid candidate Otividex, Otonomy Inc. (NASDAQ:$OTIC) saw its investors parachuting out of their shares. The number? A cool 81.5% decrease.
While …
Juno Therapeutics Blasting Off Today
Thanks to the $12 billion buyout of its rival, Kite Pharma (NASDAQ:$KITE) by Gilead Sciences (NASDAQ:$GILD) yesterday, Juno Therapeutics (NASDAQ:$JUNO) is having a solid day. Its shares have reached double digits for a second day …
Promising Research Spurs Gilead’s $12 Billion Acquisition of Kite
In a $12 billion acquisition announced Monday morning, Gilead Sciences Inc. (NASDAQ:$GILD) has expressed intent in purchasing Kite Pharma Inc (NASDAQ:$KITE), making an attempt to rejuvenate its revenue stream. The move was made to support …
Here’s Why FibroGen Shares Increased 49% Today
Big day for those interested in investing in biotech companies! On Tuesday, August 8, during heavy morning trade, FibroGen, Inc. (NASDAQ:$FGEN) shares increased 48.6%. It all started after the biopharmaceutical company announced positive results for …